Net Income (Loss) Attributable to Parent in USD of Emmaus Life Sciences, Inc. from Q2 2010 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Emmaus Life Sciences, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and change rate from Q2 2010 to Q3 2025.
  • Emmaus Life Sciences, Inc. Net Income (Loss) Attributable to Parent for the quarter ending 30 Sep 2025 was -$2,076,000.000, a 214% decline year-over-year.
  • Emmaus Life Sciences, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending 30 Sep 2025 was -$7,289,000.000, a 108% decline year-over-year.
  • Emmaus Life Sciences, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$6,453,000.000, a 72.9% decline from 2023.
  • Emmaus Life Sciences, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$3,733,000.000, a 64.9% increase from 2022.
  • Emmaus Life Sciences, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$10,625,000.000, a 33.4% increase from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

Emmaus Life Sciences, Inc. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$7,289,000 -$2,076,000 -$3,903,000 -2.1% 01 Jul 2025 30 Sep 2025 10-Q 14 Nov 2025
Q2 2025 -$3,386,000 -$1,135,000 +$1,049,000 +48% 01 Apr 2025 30 Jun 2025 10-Q 14 Nov 2025
Q1 2025 -$4,435,000 -$2,330,000 +$2,018,000 +46.4% 01 Jan 2025 31 Mar 2025 10-Q 14 Nov 2025
Q4 2024 -$6,453,000 -$1,748,000 -$2,957,000 -2.4% 01 Oct 2024 31 Dec 2024 10-K 14 Apr 2025
Q3 2024 -$3,496,000 $1,827,000 +$1,760,000 +26.3% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2025
Q2 2024 -$5,256,000 -$2,184,000 -$626,000 -40.2% 01 Apr 2024 30 Jun 2024 10-Q 14 Nov 2025
Q1 2024 -$4,630,000 -$4,348,000 -$897,000 -26% 01 Jan 2024 31 Mar 2024 10-Q 14 Nov 2025
Q4 2023 -$3,733,000 $1,209,000 +$1,009,000 +5% 01 Oct 2023 31 Dec 2023 10-K 14 Apr 2025
Q3 2023 -$4,742,000 $67,000 +$458,000 01 Jul 2023 30 Sep 2023 10-Q 19 Nov 2024
Q2 2023 -$5,200,000 -$1,558,000 +$7,334,000 +82.5% 01 Apr 2023 30 Jun 2023 10-Q 19 Nov 2024
Q1 2023 -$12,534,000 -$3,451,000 -$1,909,000 -1.2% 01 Jan 2023 31 Mar 2023 10-Q 19 Nov 2024
Q4 2022 -$10,625,000 $200,000 +$7,062,000 01 Oct 2022 31 Dec 2022 10-K 03 Jul 2024
Q3 2022 -$17,687,000 -$391,000 +$2,760,000 +87.6% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023
Q2 2022 -$20,447,000 -$8,892,000 -$11,381,000 -4.6% 01 Apr 2022 30 Jun 2022 10-Q 14 Nov 2023
Q1 2022 -$9,066,000 -$1,542,000 +$6,880,000 +81.7% 01 Jan 2022 31 Mar 2022 10-Q 14 Nov 2023
Q4 2021 -$15,946,000 -$6,862,000 -$6,595,000 -24.7% 01 Oct 2021 31 Dec 2021 10-K 31 Mar 2023
Q3 2021 -$9,351,000 -$3,151,000 -$8,736,000 -1.6% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022
Q2 2021 -$615,000 $2,489,000 +$11,962,000 01 Apr 2021 30 Jun 2021 10-Q 14 Nov 2022
Q1 2021 -$12,577,000 -$8,422,000 -$13,931,000 -2.5% 01 Jan 2021 31 Mar 2021 10-Q 14 Nov 2022
Q4 2020 $1,354,000 -$267,000 +$1,179,000 +81.5% 01 Oct 2020 31 Dec 2020 10-K 31 Mar 2022
Q3 2020 $175,000 $5,585,000 +$23,977,000 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2021
Q2 2020 -$23,802,000 -$9,473,000 +$8,123,000 +46.2% 01 Apr 2020 30 Jun 2020 10-Q 12 Nov 2021
Q1 2020 -$31,925,000 $5,509,000 +$22,917,000 01 Jan 2020 31 Mar 2020 10-Q 12 Nov 2021
Q4 2019 -$54,842,000 -$1,446,000 +$931,500 +39.2% 01 Oct 2019 31 Dec 2019 10-K/A 10 Aug 2021
Q3 2019 -$55,773,500 -$18,392,000 -$32,961,000 -2.3% 01 Jul 2019 30 Sep 2019 10-Q 26 Aug 2021
Q2 2019 -$22,812,500 -$17,596,000 +$29,749,000 +62.8% 01 Apr 2019 30 Jun 2019 10-Q 26 Aug 2021
Q1 2019 -$52,561,500 -$17,408,000 -$14,820,700 -5.7% 01 Jan 2019 31 Mar 2019 10-Q 26 Aug 2021
Q4 2018 -$37,740,800 -$2,377,500 +$391,800 +14.1% 01 Oct 2018 31 Dec 2018 10-Q 14 Feb 2019
Q3 2018 -$38,132,600 $14,569,000 +$17,217,200 01 Jul 2018 30 Sep 2018 10-Q 13 Nov 2019
Q2 2018 -$55,349,800 -$47,345,000 -$45,772,600 -29.1% 01 Apr 2018 30 Jun 2018 8-K/A 14 Aug 2019
Q1 2018 -$9,577,200 -$2,587,300 -$1,135,300 -78.2% 01 Jan 2018 31 Mar 2018 10-Q 13 May 2019
Q4 2017 -$8,441,900 -$2,769,300 -$1,329,100 -92.3% 01 Oct 2017 31 Dec 2017 10-Q 14 Feb 2019
Q3 2017 -$7,112,800 -$2,648,200 -$1,655,700 -1.7% 01 Jul 2017 30 Sep 2017 10-K 11 Dec 2018
Q2 2017 -$5,457,100 -$1,572,400 -$218,000 -16.1% 01 Apr 2017 30 Jun 2017 10-Q 10 Aug 2018
Q1 2017 -$5,239,100 -$1,452,000 -$1,309,300 -9.2% 01 Jan 2017 31 Mar 2017 10-Q 14 May 2018
Q4 2016 -$3,929,800 -$1,440,200 +$2,011,100 +58.3% 01 Oct 2016 31 Dec 2016 10-Q 20 Feb 2018
Q3 2016 -$5,940,900 -$992,500 +$279,200 +22% 01 Jul 2016 30 Sep 2016 10-K 29 Dec 2017
Q2 2016 -$6,220,100 -$1,354,400 -$817,600 -1.5% 01 Apr 2016 30 Jun 2016 10-Q 14 Aug 2017
Q1 2016 -$5,402,500 -$142,700 +$553,600 +79.5% 01 Jan 2016 31 Mar 2016 10-Q 15 May 2017
Q4 2015 -$5,956,100 -$3,451,300 -$2,576,700 -2.9% 01 Oct 2015 31 Dec 2015 10-Q/A 30 Mar 2017
Q3 2015 -$3,379,400 -$1,271,700 -$434,600 -51.9% 01 Jul 2015 30 Sep 2015 10-K 22 Dec 2016
Q2 2015 -$2,944,800 -$536,800 +$482,000 +47.3% 01 Apr 2015 30 Jun 2015 10-Q 15 Aug 2016
Q1 2015 -$3,426,800 -$696,300 +$245,700 +26.1% 01 Jan 2015 31 Mar 2015 10-Q 16 May 2016
Q4 2014 -$3,672,500 -$874,600 -$1,009,700 -7.5% 01 Oct 2014 31 Dec 2014 10-Q 17 Feb 2016
Q3 2014 -$2,662,800 -$837,100 +$6,231,800 +88.2% 01 Jul 2014 30 Sep 2014 10-K 05 Jan 2016
Q2 2014 -$8,894,600 -$1,018,800 +$315,200 +23.6% 01 Apr 2014 30 Jun 2014 10-Q 14 Aug 2015
Q1 2014 -$9,209,800 -$942,000 +$589,200 +38.5% 01 Jan 2014 31 Mar 2014 10-Q 18 May 2015
Q4 2013 -$9,799,000 $135,100 +$1,108,400 01 Oct 2013 31 Dec 2013 10-Q 13 Feb 2015
Q3 2013 -$10,907,400 -$7,068,900 -$11,172,700 -2.7% 01 Jul 2013 30 Sep 2013 10-K 29 Dec 2014
Q2 2013 $265,300 -$1,334,000 -$4,949,200 -1.4% 01 Apr 2013 30 Jun 2013 10-Q 14 Aug 2014
Q1 2013 $5,214,500 -$1,531,200 +$6,863,300 +81.8% 01 Jan 2013 31 Mar 2013 10-Q 15 May 2014
Q4 2012 -$1,648,800 -$973,300 +$1,758,000 +64.4% 01 Oct 2012 31 Dec 2012 10-Q 13 Feb 2014
Q3 2012 -$3,406,800 $4,103,800 +$6,799,800 01 Jul 2012 30 Sep 2012 10-K 23 Dec 2013
Q2 2012 -$10,206,600 $3,615,200 +$2,741,800 +3.1% 01 Apr 2012 30 Jun 2012 10-Q 14 Aug 2013
Q1 2012 -$12,948,400 -$8,394,500 -$1,448,200 -20.8% 01 Jan 2012 31 Mar 2012 10-Q 15 May 2013
Q4 2011 -$11,500,200 -$2,731,300 -$2,633,600 -27% 01 Oct 2011 31 Dec 2011 10-Q/A 22 Feb 2013
Q3 2011 -$8,866,600 -$2,696,000 01 Jul 2011 30 Sep 2011 10-K 15 Jan 2013
Q2 2011 $873,400 +$2,373,600 01 Apr 2011 30 Jun 2011 10-Q/A 11 Sep 2012
Q1 2011 -$6,946,300 01 Jan 2011 31 Mar 2011 10-Q 15 May 2012
Q4 2010 -$97,700 01 Oct 2010 31 Dec 2010 10-Q 14 Feb 2012
Q2 2010 -$1,500,200 01 Apr 2010 30 Jun 2010 10-Q/A 09 Sep 2011

Emmaus Life Sciences, Inc. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$6,453,000 -$2,720,000 -72.9% 01 Jan 2024 31 Dec 2024 10-K 14 Apr 2025
2023 -$3,733,000 +$6,892,000 +64.9% 01 Jan 2023 31 Dec 2023 10-K 14 Apr 2025
2022 -$10,625,000 +$5,321,000 +33.4% 01 Jan 2022 31 Dec 2022 10-K 03 Jul 2024
2021 -$15,946,000 -$17,300,000 -12.8% 01 Jan 2021 31 Dec 2021 10-K 31 Mar 2023
2020 $1,354,000 +$56,196,000 01 Jan 2020 31 Dec 2020 10-K 31 Mar 2022
2019 -$54,842,000 +$17,745,000 +24.4% 01 Jan 2019 31 Dec 2019 10-K/A 10 Aug 2021
2018 -$72,587,000 -$65,474,200 -9.2% 01 Jan 2018 31 Dec 2018 10-K 25 Jan 2021
2017 -$7,112,800 -$1,171,900 -19.7% 01 Oct 2016 30 Sep 2017 10-K 11 Dec 2018
2016 -$5,940,900 -$2,561,500 -75.8% 01 Oct 2015 30 Sep 2016 10-K 29 Dec 2017
2015 -$3,379,400 -$716,600 -26.9% 01 Oct 2014 30 Sep 2015 10-K 22 Dec 2016
2014 -$2,662,800 +$8,244,600 +75.6% 01 Oct 2013 30 Sep 2014 10-K 05 Jan 2016
2013 -$10,907,400 -$7,500,600 -2.2% 01 Oct 2012 30 Sep 2013 10-K 29 Dec 2014
2012 -$3,406,800 +$5,459,800 +61.6% 01 Oct 2011 30 Sep 2012 10-K 23 Dec 2013
2011 -$8,866,600 -$692,600 -8.5% 01 Oct 2010 30 Sep 2011 10-K 15 Jan 2013
2010 -$8,174,000 01 Oct 2009 30 Sep 2010 10-K 22 Dec 2011
* An asterisk sign (*) next to the value indicates that the value is likely invalid.